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Abstract: This paper documents the process by which we, through gene and miRNA expression
profiling of the same samples of head and neck squamous cell carcinomas (HNSCC) and an integrative
miRNA-mRNA expression analysis, were able to identify candidate biomarkers of progression-free
survival (PFS) in patients treated with cetuximab-based approaches. Through sparse partial least
square–discriminant analysis (sPLS-DA) and supervised analysis, 36 miRNAs were identified
in two components that clearly separated long- and short-PFS patients. Gene set enrichment
analysis identified a significant correlation between the miRNA first-component and EGFR signaling,
keratinocyte differentiation, and p53. Another significant correlation was identified between the
second component and RAS, NOTCH, immune/inflammatory response, epithelial–mesenchymal
transition (EMT), and angiogenesis pathways. Regularized canonical correlation analysis of sPLS-DA
miRNA and gene data combined with the MAGIA2 web-tool highlighted 16 miRNAs and 84 genes
that were interconnected in a total of 245 interactions. After feature selection by a smoothed t-statistic
support vector machine, we identified three miRNAs and five genes in the miRNA-gene network
whose expression result was the most relevant in predicting PFS (Area Under the Curve, AUC = 0.992).
Overall, using a well-defined clinical setting and up-to-date bioinformatics tools, we are able to give
the proof of principle that an integrative miRNA-mRNA expression could greatly contribute to the
refinement of the biology behind a predictive model.
Keywords: miRNA; microarray; head and neck squamous cell carcinomas (HNSCC); cetuximab;
drug sensitivity
1. Introduction
Head and neck cancers develop in the mucosal linings of the upper aerodigestive tract and
over 90% are squamous cell carcinomas (HNSCC). The disease is diagnosed in advanced stages
(stage III and IV) in the majority of patients and their treatment usually requires surgery, radiation
therapy, or chemotherapy in different combinations [1]. However, 27%–50% of cases relapse within
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two years after treatment, and platinum-based chemotherapy (CT) plus a targeted therapy with an
anti-EGFR (epidermal growth factor receptor) monoclonal antibody (mAb), cetuximab, is usually
offered to recurrent or metastatic (RM) patients.
This systemic treatment still represents that achieving major improvement in RM-HNSCC patients
in the last decade [2]. Since only about 40% of patients benefit from a response to this drug combination,
and only a small portion of this group experience durable responses, clinicians are faced with the
problem of choosing the best curative treatment without the help of reliable predictive biomarkers.
In the last 15 years we have observed continuous improvements in genomics, enabling the
molecular profiling of over 20,000 genes and 2000 microRNAs (miRNAs). Similarly, there have been
improvements in bioinformatics through the continuous development of new algorithms to integrate
these two types of highly dimensional “omics” data [3].
Recent work has shown that by analyzing gene expression profiling of a selected retrospective
series of HNSCC patients, and by associating it to the response/sensitivity to cetuximab-CT,
we were able to propose that long-progression-free survival (PFS) cases behave in a manner consistent
with a defined molecular subgroup. This subgroup has a poor prognosis, which can be rescued
by cetuximab/CT treatment, while short-PFS cases are characterized by an over-activation of RAS
signaling [4].
Taking advantage of the same HNSCC clinical materials, and on the basis of our successful
analyses of other cancer types for biological characterization [5] or for prognostication [6], we profiled
miRNAs and we performed an integrated miRNA-mRNA expression analysis to further gain insight
into the biology and prediction of the cetuximab-CT response.
2. Materials and Methods
2.1. Patients and Study Design
Forty tumor specimens from RM-HNSCC patients were divided according to PFS following
cetuximab-CT treatment in 14 long-PFS patients and 26 short-PFS patients [4]. The study design
includes two groups balanced for known prognostic factors [7] (primary tumor site, performance
status, weight loss, prior radiotherapy, tumor grade, residual disease at primary tumor site, age, and
gender). Long-PFS had a median PFS of 19 months (range 12–36), while short-PFS had a median PFS of
three months (range 1–5.5). The study was conducted in accordance with the Declaration of Helsinki
and was approved by the Independent Ethics Committee of Fondazione IRCCS Istituto Nazionale dei
Tumori (Approval Number 55/12).
2.2. miRNA Profiling
Total RNA was extracted from formalin fixed paraffin embedded (FFPE) tissues using the
miRNeasy FFPE kit (Qiagen, Valencia, CA, USA), and concentration was assessed with the NanoDrop
ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA was processed for
miRNA profiling according to the manufacturer′s recommendations, and miRNA expression analysis
was performed using SurePrint G3 Human miRNA 8×60K microarrays from Agilent Technologies
(Santa Clara, CA, USA). RNA was dephosphorylated in the amount of 100 ng with calf intestinal
alkaline phosphatase and denatured by DMSO treatment. Samples were labeled with cyanine 3-pCp
using T4 RNA ligase and hybridized on miRNA array. Arrays were washed in Agilent′s Wash Buffers
and scanned at a resolution of 2 mm using an Agilent DNA microarray scanner (Agilent Technologies).
Primary data were collected using Agilent′s Feature Extraction software v10.7 (Agilent Technologies).
Raw miRNA expression data were processed using an optimized version of the Robust Multi-array
Average (RMA) algorithm implemented in AgiMicroRna package [8]. Based on gIsGeneDetected
information provided by the Agilent′s Feature Extraction software, miRNAs detected in at least 10%
of samples were selected, yielding a data matrix containing 614 miRNAs. Microarray data were
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deposited and are available on NCBI Gene Expression Omnibus (GEO) database [9] with the accession
number GSE92595.
2.3. Statistical and Bioinformatics Analyses
2.3.1. miRNA Expression Analysis
To identify expression patterns related to patient′s PFS, we applied two different approaches:
(i) discriminant analysis aimed at identifying features whose expression differences help stratifying
patients; (ii) differential expression analysis aimed at obtaining a list of features whose expression
differs among classes. In general, a discriminant feature is differentially expressed, but the reverse is
not always true. Among discriminant methods, we used the sparse partial least square–discriminant
analysis (sPLS-DA) [10] applying mixOmics R package [11] from Bioconductor [12], since in
comparative studies it resulted in efficient generalization ability [13]. sPLS-DA is a pattern recognition
technique that enables disclosing a set of features in a supervised classification context that are
summarized in appropriate linear combinations performing variable selection and classification in
a single step procedure. This approach has already been successfully applied to miRNA analysis in
a setting where the number of samples is limited compared to the number of tested miRNAs [14].
The discriminative miRNAs were selected on the miRNA data matrix named X (n × p), where n is the
number of samples and p is the total number of variables (i.e., miRNAs). In our analysis, the size is
n = 40 samples and p = 614 miRNAs. The selection was based on the response dummy matrix
partitioned in K groups (K = 2), where K is the number of classes. Two parameters should be tuned in
sPLS-DA: the number of discriminant vectors and the number of variables to select on each dimension
(PLS component). According to further literature [10], it is conventional to choose the number of
sPLS-DA dimensions H ≤ min (p, K). We tested the performance in terms of the classification error rate
with a maximum distances prediction method for the first 10 sPLS-DA dimensions, which included a
number of miRNAs ranging from 1 to 50 in each dimension. A 10-fold cross-validation setting was
imposed and the “optimal” number of variables was finally determined when the lowest error rate is
obtained. Differential expression analysis, imposing the same criteria of Bossi et al. [4], was performed
on miRNA expression data, and through a random variance t-test that improved estimates without
assuming that all miRNA have the same variance. A False Discovery Rate (FDR, [15]) correction was
applied on raw p-values and a threshold of 0.15 was set. A global test to ascertain the differences in
expression patterns between classes was performed through random permutations of the class labels.
For each random permutation, all t-tests are re-computed for each miRNA and the proportion of the
random permutations that gave as many miRNA significant at FDR < 0.15 as were found in comparing
the true class labels was assessed providing a p-value. BRB-ArrayTools (version 4.3.1) developed by
Dr. Richard Simon and the BRB-ArrayTools Development Team, available at [16] was used for
differential expression analysis.
2.3.2. Inference of miRNA Components on Gene Expression Data by GSEA
Pathway enrichment analysis was carried out by gene set enrichment analysis (GSEA) using the
dataset GSE65021 [4] and the GSEA 2.2.2 software [17]. The first and second components of miRNA
sPLS-DA defined the two continuous traits to which gene-expression data were ranked through GSEA,
determining gene-sets having either positive or negative correlations. Pearson correlation was used as
the metrics for ranking genes, and phenotype permutation was performed to assess the significance of
the enrichment scores. For multiple testing adjustments, Benjamini and Hochberg′s false discovery
rate was applied. FDRs were calculated on the normalized enrichment scores (NES) and only gene-sets
enriched with an FDR < 0.05 were retained. GSEA was performed on Molecular Signatures Database
(MSigDB; v5.1 updated January 2016, http://software.broadinstitute.org/gsea/msigdb), including
C5 collection associated with GO terms, C6 oncogenic signatures corresponding to cellular pathways
dis-regulated in cancer by specific oncogenes, and Hallmark, a collection of gene-sets aggregating many
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MSigDB redundant terms to represent well-defined biological processes. Graphical representation of
the most significant gene-sets was provided by GOBubble function available in GOplot R package [18],
displaying information about the significance of the enrichment (−log10 p-value) and the z-score of
each gene set.
2.3.3. Differential Gene Expression Analysis by sPLS-DA
The procedure described in Section 2.3.1. for miRNA expression data was also applied on
gene-expression data corresponding to a data matrix retrieved from GEO repository under the ID
GSE65021 [4] denominated Z (n × q) whose size is 40 (samples) × 17,378 (detected features = genes).
2.3.4. miRNA and Gene-Expression Integrative Analysis
We focused our attention on analytic methods capable of establishing the potential relationships
between sets of measurements from the same samples, reducing the dimensionality of the data.
Canonical correlation analysis (CCA) is a classical technique developed by Hotelling [19] that extracts
linear correlations among sets of variables on the same set of subjects, including all variables from
both data sets. However, limited sample size and high dimensional data, which is a common situation
for genomic studies, results in inaccurate estimates and data overfitting issues [20]. Regularized
CCA (rCCA) is a modified version of CCA that implements a regularization procedure to reduce
the dimensionality of the data. This method has been already used [21] and resulted useful to
disclose linear relationships between two sets of variables. Taking into account two data matrices X
(n × p) and Z (n × q), representing miRNA and gene-expression data, respectively, where n << p and
n << q, regularization of covariance′s matrices of X and Z consists in adding a multiple of the identity
matrix (Id):
Cov(X) + λ1Id and Cov(Z) + λ2Id
The regularization parameters λ1 and λ2 were selected by 10-fold cross-validation procedure on a
regular grid of size 100 × 100 defined on the region 0.001 < λ1 < 0.05, and 0.0001 < λ2 < 0.05 using the
tune.rcc function available in mixOmics and resulting in λ1 = 0.0292 and λ2 = 0.00199 (Supplementary
Materials Figure S1A). The choice of dimensions d (1 ≤ d ≤ p) to include in further analysis was done
according to Gonzalez et al. [22] who suggests an empirical approach based on the inspection of the plot
of canonical correlations versus dimensions and on selection of the appropriate number of dimensions
before a clear gap among canonical correlations. On the basis of the obtained λ1 and λ2 parameters,
we observed a clear gap between the 23rd and the 24th canonical correlations (Supplementary Materials
Figure S1B).
The relationships between miRNAs and genes were displayed by correlation circle plots that
allow recognition of the correlation structure between the two sets of variables X and Z. In this type
of graphical representation, the variables X and Z are projected as vectors onto a plane and the
relationship (correlation) between variables is approximated by the inner product between vectors
(i.e., the product of the two vector lengths and their cosine angles). Since the variables X and Z
correspond to unit of variance, their projections are inside a circle of radius 1 centered at the origin
of the correlation plot. In this way, the correlation circle plots allow to reveal inherent features
embedded into the correlation structure of the variables. In detail, the association among variables is
disclosed by: (i) the distance from the origin (the greater the distance is, the stronger the association is);
(ii) the direction of the projection of variables from the origin (sharp angle in the same direction
meaning a positive correlation; obtuse angle in an opposite direction meaning a negative correlation; a
right angle meaning null correlation). To improve interpretability, two circles are drawn: one external
circle, radius = 1, and one internal circle. The area between the two circles reveals the most important
variables and the variables close to the center are assumed to be not relevant. By imposing in our
analysis an inner circle with radius = 0.3, the area from 0.3 to 1 contains the relevant miRNA-gene
expression relationships. rCCA results were also displayed by clustered image maps (CIM) as a
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heatmap that represents the correlation between two matched datasets. The similarity matrix obtained
by miRNA and gene-expression was organized in a bi-cluster hierarchical structure illustrating the
interplay among sets of variables [23]. The Euclidian distance and the average agglomeration method
were used for the hierarchical clustering.
2.3.5. Target Prediction
We integrated target predictions with correlation-based miRNA and gene expression profiles
based on the hypothesis that the expression profile of a given miRNA is expected to be inversely
correlated with its mRNA target if the miRNA acts on mRNA stability. Data from miRNA and gene
expression identified by rCCA were analyzed by MAGIA2 web-tool [24] to build mixed miRNA-gene
expression networks. MAGIA2 was run on the expression data for the top 75% of genes with greatest
variation in expression among samples. Three target prediction databases, DIANA-microT [25],
TargetScan [26], and microrna.org [27], were selected for miRNA target prediction using default
settings. The predictions shared by at least two of the three databases are retained and the final
network is visualized by Cytoscape [28]. To investigate the experimentally validated miRNA/gene
interactions, we retrieved the data from miRTarBase, a comprehensive repository of evidences based
on literature [29].
2.3.6. miRNA-Gene Integrative Predictive Signature
To test the feasibility in defining a miRNA-gene integrative predictive signature, a method is
required satisfying the criteria to be able to: (i) select pivotal features avoiding unnecessary redundancy;
(ii) integrate data from different sources (i.e., miRNA and gene expression). Smoothed t-statistic
support vector machine (stSVM) is a feature selection method that proved its efficiency in merging
network data by smoothing feature-wise t-statistics using a random walk kernel and the integration of
data from miRNA and gene expression profiles [30]. The method was designed to select features by
a permutation test with subsequent SVM training. Prediction performance was assessed by 10-time
repeated 10-fold cross-validation. All calculations were performed through netClass R-package [31].
2.3.7. Comparison Analysis with Publically Available Data
Level 3 files of HNSCC miRNA and gene expression data present in The Cancer Genome Atlas
(TCGA) [32] were downloaded along with the clinical annotations from the TCGA website [33]
and used for the analysis. Subtype molecular classification was performed as described in
De Cecco et al. [34] identifying Cl2-mesenchymalmesenchymal and Cl3-hypoxia subtypes.
3. Results
3.1. miRNA Expression Patterns in HNSCC Patients Treated with Cetuximab-CT
To disclose miRNA patterns associated with PFS, a supervised analysis was applied to our data
matrix of 614 detected miRNAs using sPLS-DA and imposing the “a priori” knowledge of a patient′s
PFS category (long and short PFS) [4]. sPLS-DA allows selection for variables that best separate the
two PFS categories, reducing the dimensionality of those patterns in a few discriminant components.
We assessed the classification error rate using the maximum distance method to determine the optimal
number of dimensions and features to retain. As such, the best performance (lowest misclassification
rate) was obtained, including the first two components which explained 68% of the variance in miRNA
expression; the first component (24 miRNAs), which retained a large part of the variance, explained
49% of the variance, compared to the second component (12 miRNAs), which explained 19% of the
variance (miRNA list in Supplementary Materials Table S1, panel A). The results of this analysis
showed that miRNA profiles were able to clearly separate long- and short-PFS patients (Figure 1A)
and each component significantly divided the two categories of patients (Figure 1B).
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(B)  The  box‐plot  analysis  shows  the  loading  vector  values  for  the  first  component  and  second 
component with  samples divided on  the  basis of  class  (long PFS  =  blue;  short PFS  =  orange). A 
significant  difference  was  observed  in  each  component  (first  component,  p  =  2.97E‐07;  second 
component, p = 0.00529). 
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0.013, as determined by the global test). After filtering based on |log2(fold change)| > 1, 39 miRNAs, 
four and 35 upregulated in long‐ and in short‐PFS samples, respectively, were retained (volcano plot 
in Supplementary Materials Figure S2; fold change and p‐values in Supplementary Materials Table 
S1, panel B). The comparison of the two methods (see Supplementary Materials Table S1) indicated 
that 18 of 39 differentially expressed miRNAs were included in the first component of the sPLS‐DA 
while  none  from  the  second  component were differentially  expressed  according  to  the  selection 
criteria. 
3.2. Biological Relevance of sPLS‐DA miRNAs Inferred by GSEA 
Figure 1. miRNA expression patterns in H tumors associated with PFS after cetuximab-CT
treatment: sPLS-DA identified 24 and 12 miRNAs in first and second components, respectively
(see Supplementary Materials Table S1 for list). (A) The score plot of sPLS-DA miRNA profiles of
the two components is shown and each individual patient was plotted. The well-defined clusters,
corresponding to the 14 long-PFS patients (blue dots) and the 26 short-PFS patients (orange dots), can
be identified. The lines indicate the distance from the respective centroid for samples of each class;
(B) The box-plot analysis shows the loading vector values for the first component and second
component with samples divided on the basis of class (long PFS = blue; short PFS = or ge).
A significant difference was observed in each component (first component, p = 2.97E-07;
second component, p = 0.00529).
When the same data matrix was analyzed by supervised class comparison, we identified
166 differentially expressed miRNAs (the probability of finding 166 miRNAs significant by chance was
0.013, as determined by the global test). After filtering based on |log2(fold change)| > 1, 39 miRNAs,
four and 35 upregulated in long- and in short-PFS samples, respectively, were retained (volcano plot in
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Supplementary Materials Figure S2; fold change and p-values in Supplementary Materials Table S1,
panel B). The comparison of the two methods (see Supplementary Materials Table S1) indicated that 18
of 39 differentially expressed miRNAs were included in the first component of the sPLS-DA while
none from the second component were differentially expressed according to the selection criteria.
3.2. Biological Relevance of sPLS-DA miRNAs Inferred by GSEA
In order to investigate the biological information embedded in the miRNA sPLS-DA components,
these components were correlated to gene expression data [4] and pathway recognition was performed
through GSEA. miRNAs of the first component correlated with EGFR signaling, keratinocyte
differentiation and ectoderm development (GO terms), and p53 and Myc (oncogenic signatures);
miRNAs of the second component were correlated with the oncogenic signatures RAS and NOTCH
and with numerous GO terms, including immune/inflammatory response, EMT, and angiogenesis
pathways (Figure 2).
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Figure 2. Bub l e e sets as ociated with miRNAs’ first and second components identified by
sPLS-DA: n overview of GSEA-enriched networks was depicted. The x-axis indicates the z-score f
each term, while the y-axis is the negative logarithm of t e adjusted p-value. The rea of the displayed
circles is proportional to the number of genes assigned to each term. The colors display the positive
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3.3. Integrated miR A and R A etworks
To proceed in an integrative analysis, we first applied sPLS-DA on whole-gene expression data
obtained from the same samples (see Bossi et al. for details; [4]) and following the criteria of the miRNA
profile. A lower misclassification rate was found including the first two components containing
428 unique genes; Supplementary Materials Figure S3 shows the performance in stratifying patients
based on long and short PFS. Through rCCA we tested the linear combinations between X and Z
data matrices, representing miRNA and gene expression patterns, respectively; rCCA allowed us
to highlight the most relevant correlation structures embedded into the expression data. Since the
first two variates explained most of the data variability (45% and 14% variates 1 and 2, respectively)
and retained the ability to stratify patient outcome, we restricted the analysis to these dimensions
to identify relevant miRNA–gene expression associations. The results of the integrated analysis are
displayed through a correlation circle plot (Figure 3A) in which a total of 27 miRNA and 250 genes
were shown as significantly correlated (see list in Supplementary Materials Table S2). The results
showed a separation of miRNAs and correlated genes that can be summarized in four clusters:
(i) a core of 22 miRNAs with a long distance from the center (range: from−0.945 to−0.731) in variate 2;
(ii) a cluster of 168 genes negatively correlated to miRNA variate 1 and constituting gene variate 1;
(iii) a small cluster of five miRNAs in variate 2 (range: from −032 to −0.201); (iv) a cluster of 82 genes
negatively correlated to miRNA variate 2 and constituting gene variate 2 (see Supplementary Materials
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Table S2 for details about miRNAs and genes belonging to the four clusters). To improve our
understanding of the connections between miRNAs and genes, a pair-wise similarity matrix was
computed and displayed by CIM (Figure 3B).
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highlighted that: (i) four miRNAs (hsa‐miR‐130b‐3p, hsa‐miR‐199a‐3p, hsa‐miR‐214‐3p, and hsa‐miR‐
28‐5p) accounted for 41% of the interactions; (ii) four genes (CDK5R1, KLK10, LYNX1, and TMEM79) 
were co‐targeted by eight miRNAs; (iii) several genes were targeted by several miRNAs; (iv) a survey 
using  the  miRTarBase  repository  proved  that  CD24/miR‐34a‐5p,  ITGA6/miR‐29a‐3p,  and 
L1CAM/miR‐34a‐5p were experimentally validated interactions. 
Figure 3. Identification of integrated miRNA and mRNA networks: (A) The correlation circle plot
displays the features (miRNAs = red; genes = blue) and the position derived by the combination of the
first and second variates in our rCCA. The features in the area outside the inner ring (radius < 0.3) were
retained as significant and shown in the plot. The ellipses depicted four miRNA/gene clusters and
the list can be found in Supplementary Materials Table S2; (B) The CIM plot displays the correlation
structure between the features. Each colored block represents an association between miRNAs and
genes spanning a range of colors from blue (negative correlation), to yellow (weak correlation), to red
(positive correlation). The dendrograms on the top and left side indicate how genes and miRNAs,
respectively, are connected.
3.4. Computational Integration of miRNAs and Genes by MAGIA 2
The miRNA genes identified by rCCA were integrated for network analysis using three prediction
target algorithms (DIANA-microT, TargetScan, microrna.org). By imposing a q-value < 0.1 and Pearson
correlation as an association measure, 16 miRNAs and 84 enes were interconnected (Figure 4 a d
Supplementary Materials Table S3). Analysis of the 245 identified interactions highlighted that:
(i) four miRNAs (hsa-miR-130b-3p, hsa-miR-199a-3p, hsa-miR-214-3p, and hsa-miR-28-5p) accounted
for 41% of the interactions; (ii) four genes (CDK5R1, KLK10, LYNX1, and TMEM79) were co-targeted
by eight miRNAs; (iii) several genes were targeted by several miRNAs; (iv) a survey using the
miRTarBase repository proved that CD24/miR-34a-5p, ITGA6/miR-29a-3p, and L1CAM/miR-34a-5p
were experimentally validated interactio s.
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Figure 4. Computational integration of genes and miRNAs by MAGIA2 bioinformatics tool:
The network of anticorrelated miRNA genes was computed by rCCA and integrated by MAGIA2 tools
with the information of target prediction derived from DIANA-microT, TargetScan, and microrna.org.
Two hundred and f rty-five interactions were found among 16 miRNAs and 84 genes. The Cytoscape
tool was applied t displ y th interconnections betwe n features. Yellow triangles indicate the
miRNAs, and blue boxes indicate the genes. If it is pr dicted that a g ne is to be targeted by at least
two ou of 16 miRNAs, this gene is located i the cen ral ring, comprising the iRNAs. Otherwise, it is
placed out ide.
3.5. Development of An Integrated miRNA-Gene Expression Predictive Model
We investigated to what extent the miRNA-gene integrated network could predict the outcome
in our cohort of patients. A feature selection was imposed by means of stSVM to the miRNA-gene
networks identified by rCCA, along with the adjacency matrix representing the biological interactions
found by at least two of the three target prediction algorithms applied; we expected to select the most
relevant features for predicting the outcome. As such, the results highlighted eight relevant features
(three miRNAs and five genes): hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-199b-5p, ARRDC4,
CRCT1, IL36G, KLK10, and PLA2G4E. The performance of the identified signature, as assessed
through Receiver Operator Characteristic (ROC) analysis, reached an AUC of 0.992 (Figure 5A).
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greatly contribute to a refinement in the identification of the biology behind the response to palliative
cetuximab-based treatment and to the development of a potential predictive model.
High-throughput technologies have proved to be of great potential for gaining valuable insights
into tumor biology, and even to build predictive models in HNSCC [36]. However, these data involve
a number of variables (i.e., miRNA, genes), by far over-exceeding the number of samples, resulting
in a high degree of multicollinearity and ill-conditioned issues. Many bioinformatics pipelines have
been developed to solve these issues, mainly reducing the dimensionality of the data [37]. Taking into
account a supervised classification setting, the approach involves the introduction of a new artificial
variable able to summarize most of the information present in highly correlated miRNAs or genes.
In this context, sparse partial–least squares discriminant analysis (sPLS-DA) is a well-known,
supervised, pattern-recognition method able to unravel the information contained in a data matrix in
relation to a qualitative response variable indicating classes of samples [10].
Long- and short-PFS cases were compared on the basis of their miRNA profiles using sPLS-DA.
Our results clearly indicate that miRNA profiles separated the two groups of patients well,
and the lowest misclassification rate was obtained considering a total of 36 miRNAs in two components.
When this signature was compared to a supervised class comparison, most of the miRNAs differentially
expressed by a random variance t-test–based class comparison were included in the first component
and none in the second.
In general, miRNA expression profiles provide limited information about their biological role.
In fact, miRNAs being non-coding regulators of gene expression, their function is linked not only to
their expression level, but also to those of their target genes. In this context, an integrative analysis
could help uncover the biological regulatory interactions between miRNAs and gene expression.
First of all, we investigated the association of miRNA sPLS-DA with gene expression data.
A significant correlation between first-component miRNAs and pathways enriched in long-PFS patients
(EGFR signaling, keratinocyte differentiation, ectoderm development pathways and p53 and Myc
oncogenic signatures) recapitulates our previous observations obtained by directly analyzing gene
expression [4], but also identified the association with hypoxia. An activated EGFR pathway leads
to a response to cetuximab. In this context, CD24, a mucin-like membrane glycoprotein, regulates
the expression of EGFR by preventing its internalization and RhoA-dependent degradation [38].
Our data clearly demonstrated an interaction between hsa-miR-34a-5p and its experimentally validated
target CD24, as hsa-miR-34a-5p was downregulated while CD24 was upregulated in long-PFS patients.
The combination of platinum-based chemotherapy and targeted therapy with an anti-EGFR inhibitor
represents a strategy in treating RM-HNSCC. However, little is known about the mechanism leading to
chemo-resistance [39]. It has been demonstrated that inhibition of L1 cell adhesion molecule (L1CAM)
and EGFR sensitizes cells to cisplatin [40] and our findings support a molecular loop among EGFR
signaling activation, the downregulation of hsa-miR-34a-5p and the upregulation of its L1CAM target
in long-PFS patients.
Through a meta-analysis approach of gene expression profiling data, we identified subtypes
with distinct molecular features including subtypes over-expressing hypoxia and mesenchymal
pathways [34]. By association with drug sensitivity, the hypoxia subtype shows the greatest sensitivity
to EGFR inhibitors [34]. In Bossi et al. [4], in a series of cetuximab-treated patients, we confirmed
a molecular link between long-PFS patients and the Cl3-hypoxia subtype, and between short-PFS
patients and the Cl2-mesenchymal subtype. Similar results were obtained following Keck’s subtype
stratification [41]. In addition, our integrated analysis disclosed the interplay between ITGA6,
a hypoxia-regulated gene [42], and its experimentally validated target hsa-miR-29a-3p. Remarkably,
the miRNA sPLS-DA second component, associated with short-PFS, confirmed the role of the RAS
pathway [4], and the results mainly correlated with an immune/inflammatory response hub that
comprises eight functionally related networks (immune response, inflammatory response, defense
response, cytokine production, TNFA signaling, interferon gamma, interleukin, and leukocyte
activation). In addition, inferring the gene networks associated with the miRNA sPLS-DA second
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component, we noticed a significant activation and enrichment of the epithelial–mesenchymal
transition, angiogenesis, and NOTCH pathways, in agreement with their involvement in the
Cl2-mesenchymal subtype [34]. Overall, our data strongly suggests that the miRNA sPLS-DA
not only supports the biology previously identified as associated with long and short PFS [4],
but provides new evidence. In particular, the sPLS-DA second component provides a completely
new layer of information, not captured by differential expression analysis which strongly contributed
to improving our knowledge about the biology behind the response to cetuximab-CT, and could
open the way to new therapeutic suggestions. Anti–PD-1 therapies were reported to evade the
checkpoint blockade, resulting in the reactivation of the immune system, enabling the eradication
of the host tumor and improving, eventually, patient survival [43,44]. The significant enrichment
of the immune/inflammatory pathway might suggest a potential benefit to immune therapy in
short-PFS patients.
In systems biology, a major challenge in the integration effort of multi-omics and highly
dimensional data is the extraction of meaningful information. Since it is expected that similar
expression patterns across a set of samples potentially have a functional relationship, we applied a
regularized version of canonical correlation analysis (rCCA) to explore correlation structures between
miRNA and gene quantitative features assessed on the same cohort of patients [20]. Exploratory
approaches with correlation circle plots and clustered image maps highlighted the association
between 27 miRNAs and 250 genes, proving the existence of distinct anti-correlated expression
patterns. These associations were confirmed by target prediction algorithms and in more detail.
As such, all four members of the miR-199/214 cluster, and five out of the 12 members of the
let-7 family, participate in the miRNA-mRNA network; a regulatory hub defined by four miRNAs
(hsa-miR-130b-3p, hsa-miR-199a-3p, hsa-miR-214-3p, and hsa-miR-28-5p) and their mRNA targets,
involving 41% of identified interactions, was observed.
Focusing our attention on the miRNA-gene integrated features able to stratify patients according
to their response to cetuximab-based treatment, a signature based on three miRNAs and five genes was
identified. The height miRNA-gene integrated signature showed an excellent accuracy in predicting
treatment response (AUC = 0.992), while the single features reached an AUC ranging from 0.85 to 0.90.
It was noteworthy that all three miRNAs belonged to the miR-199/214 cluster, and all five genes were
regulated by two members of the let7 family (let7d and let7i). These data, together with the observation
that when their expression was tested in HNSCC TCGA, the three miRNAs were upregulated in the
Cl2-mesenchymal subtype, while the five genes were upregulated in the Cl3-hypoxia subtype, strongly
support the hypothesis that these miRNAs and their regulated genes have a pivotal role in HSNCC
progression and sensitivity to therapy.
We are aware that miRNAs, by binding to mRNA molecules, can inhibit their translation or induce
degradation. However, most of the available tools and methods for miRNA target prediction, such as
those here applied, have been developed following the assumption of an inverse correlation between
miRNA/mRNA and they tend to miss the targets where expression repression is caused by translation
repression. Since in the future we will expect a strong improvement in the knowledge on miRNA
biology, the public availability of our miRNA and gene expression data for the scientific community at
the GEO website will enable any future analysis of the interplay between miRNAs and genes.
5. Conclusions
Overall, through gene and miRNA expression profiling of the same samples of HNSCC and an
integrative miRNA-mRNA expression analysis, we identified candidate biomarkers of PFS in patients
treated with cetuximab-based approaches. The use of a well-defined clinical settings and up-to-date
bioinformatics tools enabled to give the proof of principle that an integrative miRNA–mRNA
expression could greatly contribute to further gain insight into the biology and prediction, and
could have potential direct implications on clinical care. Since we selected patients with marked
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opposite outcomes after treatment, to transpose our predictor of response into a useful clinical grade
assay, additional work is needed.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/8/1/35/s1.
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analysis, Figure S3: Gene expression sPLS-DA in patients treated with cetuximab, Table S1: miRNA identified by
supervised analysis using sPLS-DA and by supervised class comparison analysis, Table S2: List of 27 miRNA and
250 genes identified by rCCA, Table S3: List of the 245 interactions disclosed by MAGIA2 tool.
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